Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: A perspective review

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 3, 2015, Pages 97-114

  Iadarola, Nicolas D ^a   Niciu, Mark J ^a   Richards, Erica M ^a   Vande Voort, Jennifer L ^a   Ballard, Elizabeth D ^a   Lundin, Nancy B ^a   Nugent, Allison C ^a   Machado Vieira, Rodrigo ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antagonist; Bipolar depression; Bipolar disorder; Glutamate; Ketamine; Major depressive disorder; N methyl D aspartate receptor; NR2B; Treatment resistant depression

Indexed keywords

AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

BECK DEPRESSION INVENTORY; BIPOLAR DEPRESSION; DENDRITIC SPINE; DEPRESSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; SYNAPTOGENESIS;

EID: 84930516190     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315579059     Document Type: Review

References (103)

1. aan het Rot M. Collins K. Murrough J. Perez A. Reich D. Charney D. et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67: 139–145.
2. Abdallah C. Fasula M. Kelmendi B. Sanacora G. Ostroff R. (2012) Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT 28: 157–161.
3. Abdallah C. Salas R. Jackowski A. Baldwin P. Sato J. Mathew S. (2014) Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. Epub ahead of print 13 August 2014. doi: 10.1177/0269881114544776.
4. Anand A. Gunn A. Barkay G. Karne H. Nurnberger J. Mathew S. et al. (2012) Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 14: 64–70.
5. Andreasen J. Gynther M. Rygaard A. Bøgelund T. Nielsen S. Clausen R. et al. (2013) Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests. Neurosci Lett 546: 6–10.
6. Autry A. Adachi M. Nosyreva E. Na E. Los M. Cheng P. et al. (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91–95.
7. Ballard E. Ionescu D. Vande Voort J. Niciu M. Richards E. Luckenbaugh D. et al. (2014) Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res 58: 161–166.
8. Berman R. Cappiello A. Anand A. Oren D. Heninger G. Charney D. et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351–354.
9. Beurel E. Song L. Jope R. (2011) Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 16: 1068–1070.
10. Blier P. Zigman D. Blier J. (2012) On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry 72: e11–e12.
11. Centers for Disease Control and Prevention (2014) Key Data and Statistics. Injury Prevention and Control. Center for Disease Control and Prevention. Available at: www.cdc.gov/injury/overview/data.html (accessed 18 March 2015).
12. Chilukuri H. Reddy N. Pathapati R. Manu A. Jollu S. Shaik A. (2014) Acute antidepressant effects if intramuscular versus intravenous ketamine. Indian J Psychol Med 36: 71–76.
13. Chowdhury G. Behar K. Cho W. Thomas M. Rothman D. Sanacora G. (2012) 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry 71: 1022–1025.
14. Cusin C. Hilton G. Nierenberg A. Fava M. (2012) Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 169: 868–869.
15. de Gioannis A. de Leo D. (2014) Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry 48: 686.
16. Diamond P. Farmery A. Atkinson S. Haldar J. Williams N. Cowen P. et al. (2014) Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 28: 536–544.
17. DiazGranados N. Ibrahim L. Brutsche N. Ameli R. Henter I. Luckenbaugh D. et al. (2010 a) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71: 1605–1611.
18. DiazGranados N. Ibrahim L. Brutsche N. Newberg A. Kronstein P. Khalife S. et al. (2010 b) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793–802.
19. Domino E. (2010) Taming the ketamine tiger. 1965. Anesthesiology 113: 678–684
20. Duman R. Aghajanian G. (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338: 68–72.
21. Duman R. Li N. Liu R. Duric V. Aghajanian G. (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62: 35–41.
22. Ghasemi M. Raza M. Dehpour A. (2010) NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacology 24: 585–594.
23. Gideons E. Kavalali E. Monteggia L. (2014) Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA 111: 8649–8654.
24. Glue P. Gulati A. Le Nedelec M. Duffull S. (2011) Dose- and exposure-response to ketamine in depression. Biol Psychiatry 70: e9–e10; author reply e11–e12.
25. Haile C. Murrough J. Iosifescu D. Chang L. Al Jurdi R. Foulkes A. et al. (2014) Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17: 331–336.
26. Han K. Holder J. Schaaf C. Lu H. Chen H. Kang H. et al. (2013) SHANK 3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 503: 72–77.
27. Harihar C. Dasari P. Srinivas J. (2013) Intramuscular ketamine in acute depression: a report on two cases. Indian J Psychiatry 55: 186–188.
28. Hay N. Sonenberg N. (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926–1945.
29. Heresco-Levy U. Gelfin G. Bloch B. Levin R. Edelman S. Javitt D. et al. (2013) A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 16: 501–506.
30. Heresco-Levy U. Javitt D. Gelfin Y. Gorelik E. Bar M. Blanaru M. et al. (2006) Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 93: 239–243.
31. Hoeffer C. Klann E. (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33: 67–75.
32. Ibrahim L. Diazgranados N. Franco-Chaves J. Brutsche N. Henter I. Kronstein P. et al. (2012 a) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37: 1526–1533.
33. Ibrahim L. DiazGranados N. Jolkovsky L. Brutsche N. Luckenbaugh D. Herring W. et al. (2012 b) A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 32: 551–557.
34. Insel T. (2012) Next-generation treatments for mental disorders. Sci Trans Med 4: 155–164.
35. Ionescu D. Luckenbaugh D. Niciu M. Richards E. Slonena E. Vande Voort J. et al. (2014) Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry 75: e932–e938.
36. Irwin S. Iglewicz A. (2010) Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 13: 903–908.
37. Irwin S. Iglewicz A. Nelesen R. Lo J. Carr C. Romero S. et al. (2013) Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med 16: 958–965.
38. Järventausta K. Chrapek W. Kampman O. Tuohimaa K. Björkqvist M. Häkkinen H. et al. (2013) Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT 29: 158–161.
39. Koike H. Chaki S. (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY 341495 during the forced swim test in rats. Behav Brain Res 271: 111–115.
40. Kollmar R. Markovic K. Thürauf N. Schmitt H. Kornhuber J. (2008) Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry 42: 170.
41. Laje G. Lally N. Mathews D. Brutsche N. Chemerinski A. Akula N. et al. (2012) Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72: e27–e28.
42. Lally N. Nugent A. Luckenbaugh D. Ameli R. Roiser J. Zarate C. Jr (2014) Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 4: e469.
43. Lapidus K. Levitch C. Perez A. Brallier J. Parides M. Soleimani L. et al. (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry, 76: 970–976.
44. Lara D. Bisol L. Munari L. (2013) Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 16: 2111–2117.
45. Larkin G. Beautrais A. (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14: 1127–1131.
46. Li N. Lee B. Liu R. Banasr M. Dwyer J. Iwata M. et al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959–964.
47. Li N. Liu R. Dwyer J. Banasr M. Lee B. Son H. et al. (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754–761.
48. Lineberry T. O'Connor S. (2012) Suicide in the US Army. Mayo Clin Proc 87: 871–878.
49. Liu R. Fuchikami M. Dwyer J. Lepack A. Duman R. Aghajanian G. (2013) GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 38: 2268–2277.
50. Luckenbaugh D. Niciu M. Ionescu D. Nolan N. Richards E. Brutsche N. et al. (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 159: 56–61.
51. Lundin N. Niciu M. Luckenbaugh D. Ionescu D. Richards E. Vande Voort J. et al. (2014) Baseline vitamin B 12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry 47: 141–144.
52. Machado-Vieira R. Yuan P. Brutsche N. DiazGranados N. Luckenbaugh D. Manji H. et al. (2009) Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 70: 1662–1666.
53. Maeng S. Zarate C. Jr Du J. Schloesser R. McCammon J. Chen G. et al. (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349–352.
54. Malkesman O. Austin D. Tragon T. Wang G. Rompala G. Hamidi A. et al. (2012) Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol 15: 1135–1148.
55. Mathew S. Murrough J. aan het Rot M. Collins K. Reich D. Charney D. (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13: 71–82.
56. Mathew S. Shah A. Lapidus K. Clark C. Jarun N. Ostermeyer B. et al. (2012) Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26: 189–204.
57. McKinney R. Capogna M. Dürr R. Gähwiler B. Thompson S. (1999) Miniature synaptic events maintain dendritic spines via AMPA receptor activation. Nat Neurosci 2: 44–49.
58. Mealing G. Lanthorn T. Murray C. Small D. Morley P. (1999) Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther 288: 204–210.
59. Moaddel R. Luckenbaugh D. Xie Y. Villaseñor A. Brutsche N. Machado-Vieira R. et al. (2014) D-serine plasma concentration is a potential biomarker of (R, S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) 232: 399–409.
60. Moghaddam B. Adams B. Verma A. Daly D. (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921–2927.
61. Morgan C. Duffin S. Hunt S. Monaghan L. Mason O. Curran H. (2012) Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis (‘skunk’) or on cocaine. Pharmacopsychiatry 45: 269–274.
62. Morgan C. Muetzelfeldt L. Curran H. (2009) Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104: 77–87.
63. Morgan C. Muetzelfeldt L. Curran H. (2010) Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 105: 121–133.
64. Morgan C. Rees H. Curran H. (2008) Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med 38: 1331–1340.
65. Mullard A. (2013) 2012 FDA drug approvals. Nat Rev Drug Discov 12: 87–90.
66. Müller H. Wegener G. Liebenberg N. Zarate C. Jr Popoli M. Elfving B. (2013) Ketamine regulates the presynaptic release machinery in the hippocampus. J Psychiatr Res 47: 892–899.
67. Murrough J. Iosifescu D. Chang L. Al Jurdi R. Green C. Perez A. et al. (2013 a) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170: 1134–1142.
68. Murrough J. Perez A. Pillemer S. Stern J. Parides M. aah het Rot M. et al. (2013 b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250-256.
69. Niciu M. Grunschel B. Corlett P. Pittenger C. Bloch M. (2013 a) Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol 27: 651–654.
70. Niciu M. Henter I. Luckenbaugh D. Zarate Jr, C. Charney D. (2014 a) Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 54: 119–139.
71. Niciu M. Ionescu D. Mathews D. Richards E. (2013 b) Second messenger / signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectr 18: 231–241.
72. Niciu M. Kelmendi B. Sanacora G. (2012) Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav 100: 656–664.
73. Niciu M. Luckenbaugh D. Ionescu D. Guevara S. Machado-Vieira R. Richards E. et al. (2014 b) Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 75: e417–e423.
74. Niciu M. Luckenbaugh D. Ionescu D. Mathews D. Richards E. Zarate C. Jr (2013 c) Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry 74: e23–e24.
75. Niciu M. Mathews D. Nugent A. Ionescu D. Furey M. Richards E. et al. (2014 c) Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety 31: 297–307.
76. Nugent A. Diazgranados N. Carlson P. Ibrahim L. Luckenbaugh D. Brutsche N. et al. (2014) Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord 16: 119–128.
77. Ortiz R. Niciu M. Lukkahati N. Saligan L. Nugent A. Luckenbaugh D. et al. (2014) SHANK 3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord 172C: 307–311.
78. Paslakis G. Gilles M. Meyer-Lindenberg A. Deuschle M. (2010) Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 43: 33–35.
79. Permoda-Osip A. Dorszewska J. Bartkowska-Sniatkowska A. Chlopocka-Wozniak M. Rybakowski J. (2013) Vitamin B 12 level may be related to the efficacy of a single ketamine infusion in bipolar depression. Pharmacopsychiatry 46: 227-228.
80. Permoda-Osip A. Skibińska M. Bartkowska-Sniatkowska A. Kliwicki S. Chłopocka-Woźniak M. Rybakowski J. (2014) [Factors connected with efficacy of single ketamine infusion in bipolar depression]. Psychiatr Pol 48: 35–47.
81. Perry E. Cramer J. Cho H. Petrakis I. Karper L. Genovese A. et al. (2007) Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 192: 253–260.
82. Phelps L. Brutsche N. Moral J. Luckenbaugh D. Manji H. Zarate C. Jr (2009) Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonists. Biol Psychiatry 65: 181–184.
83. Preskorn S. Baker B. Kolluri S. Menniti F. Krams M. Landen J. (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28: 631–637.
84. Price R. Iosifescu D. Murrough J. Chang L. Al Jurdi R. Iqbal S. et al. (2014) Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 31: 335–343.
85. Price R. Nock M. Charney D. Mathew S. (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66: 522–526.
86. Quan M. Zhang N. Wang Y. Zhang T. Yang Z. (2011) Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience 182: 88–97.
87. Rasmussen K. Lineberry T. Galardy C. Kung S. Lapid M. Palmer B. et al. (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27: 444–450.
88. Réus G. Stringari R. Kirsch T. Fries G. Kapczinski F. Roesler R. et al. (2010) Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull 81: 585–589.
89. Rybakowski J. Permoda-Osip A. Skibinska M. Adamski R. Bartkowska-Sniatkowska A. (2013) Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol 28: 87–90.
90. Sanacora G. Johnson M. Khan A. Atkinson S. Risenberg R. Schronen J. et al. (2014 a) Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebo-controlled study (PURSUIT). Poster presented on 18 June at the 2014 American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, FL.
91. Sanacora G. Smith M. Pathak S. Su H. Boeijinga P. McCarthy D. et al. (2014 b) Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19: 978–985.
92. Sanacora G. Zarate C. Jr Krystal J. Manji H. (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7: 426–437.
93. Sos P. Klirova M. Novak T. Kohutova B. Horacek J. Palenicek T. (2013) Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 34: 287–293.
94. Trullas R. Skolnick P. (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185: 1–10.
95. Valentine G. Mason G. Gomez R. Fasula M. Watzl J. Pittman B. et al. (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [ (1)H]-MRS. Psychiatry Res 191: 122–127.
96. Villaseñor A. Ramamoorthy A. Silva dos Santos M. Lorenzo M. Laje G. Zarate C. Jr et al. (2014) A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol 171: 2230–2242.
97. Wan L. Levitch C. Perez A. Brallier J. Iosifescu D. Chang L. et al. (2014) Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 2 September (epub ahead of print).
98. White P. Ham J. Way W. Trevor A. (1980) Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52: 231–239.
99. Zarate C. Jr Brutsche N. Ibrahim L. Franco-Chaves J. Diazgranados N. Cravchik A. et al. (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71: 939–946.
100. Zarate C. Jr Mathews D. Ibrahim L. Chaves J. Marquardt C. Ukoh I. et al. (2013) A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74: 257–264.
101. Zarate C. Jr Singh J. Carlson P. Brutsche N. Ameli R. Luckenbaugh D. et al. (2006 a) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856–864.
102. Zarate C. Jr Singh J. Quiroz J. de Jesus G. Denicoff K. Luckenbaugh D. et al. (2006 b) A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163: 153–155.
103. Zhou W. Dong L. Wang N. Shi J. Yang J. Zuo Z. et al. (2014) Akt mediates GSK-3β phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions. Neuroimmunomodulation 21: 183–188.